Two-year longitudinal trajectory patterns of albuminuria and subsequent rates of end-stage kidney disease and all-cause death: a nationwide cohort study of biopsy-proven diabetic kidney disease.


Journal

BMJ open diabetes research & care
ISSN: 2052-4897
Titre abrégé: BMJ Open Diabetes Res Care
Pays: England
ID NLM: 101641391

Informations de publication

Date de publication:
08 2021
Historique:
received: 25 02 2021
accepted: 08 07 2021
entrez: 13 8 2021
pubmed: 14 8 2021
medline: 13 10 2021
Statut: ppublish

Résumé

Data on the association between longitudinal trajectory patterns of albuminuria and subsequent end-stage kidney disease (ESKD) and all-cause mortality in diabetic kidney disease (DKD) are sparse. Drawing on nationally representative data of 329 patients with biopsy-proven DKD and an estimated glomerular filtration rate above 30 mL/min/1.73 m A total of three trajectory groups of UACR were identified: 'high-increasing' group (n=254; 77.2%), 'high-decreasing' group (n=24; 7.3%), and 'low-stable' group (n=51; 15.5%). The 'low-stable' group had the most favorable risk profile, including the baseline UACR (median (IQR) UACR (mg/g creatinine): 'low-stable', 109 (50-138); 'high-decreasing', 906 (468-1740); 'high-increasing', 1380 (654-2502)), and had the least subsequent risk of ESKD and all-cause death among the groups. Although there were no differences in baseline characteristics between the 'high-decreasing' group and the 'high-increasing' group, the 'high-decreasing' group had better control over blood pressure, blood glucose, and total cholesterol levels during the first 2 years of follow-up, and the incidence rates of subsequent ESKD and all-cause death were lower in the 'high-decreasing' group compared with the 'high-increasing' group (incidence rate of ESKD (per 1000 person-years): 32.7 vs 77.4, p=0.014; incidence rate of all-cause death (per 1000 person-years): 0.0 vs 25.4, p=0.007). Dynamic changes in albuminuria are associated with subsequent ESKD and all-cause mortality in DKD. Reduction in albuminuria by improving risk profile may decrease the risk of ESKD and all-cause death.

Identifiants

pubmed: 34385147
pii: 9/1/e002241
doi: 10.1136/bmjdrc-2021-002241
pmc: PMC8362707
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Diabetes Care. 2019 May;42(5):891-902
pubmed: 30833372
Lancet Diabetes Endocrinol. 2015 May;3(5):382-91
pubmed: 25943757
JAMA Cardiol. 2018 Feb 1;3(2):155-163
pubmed: 29214305
Kidney Int. 2003 Jan;63(1):225-32
pubmed: 12472787
Cardiovasc Diabetol. 2015 Apr 18;14:38
pubmed: 25909295
Arch Intern Med. 2008 Dec 8;168(22):2440-7
pubmed: 19064828
Int J Biostat. 2008;4(1):Article 14
pubmed: 22462120
Nephrol Dial Transplant. 2009 Apr;24(4):1212-9
pubmed: 18984626
JAMA. 2003 Jun 25;289(24):3273-7
pubmed: 12824208
Diabetes Care. 2021 Jan;44(Suppl 1):S151-S167
pubmed: 33298422
Diabetes Care. 2009 Aug;32(8):1497-502
pubmed: 19470839
Ren Fail. 2016;38(3):481-3
pubmed: 26822401
Diabetes Care. 2013 Oct;36(10):3227-33
pubmed: 23780946
Diabetes. 1995 May;44(5):561-4
pubmed: 7729616
Diabetes Care. 2004 Jan;27(1):195-200
pubmed: 14693989
J Am Soc Nephrol. 2009 Aug;20(8):1813-21
pubmed: 19443635
BMJ. 2016 Feb 11;352:i438
pubmed: 26868137
Lancet. 1992 Aug 8;340(8815):319-23
pubmed: 1353802
Clin Exp Nephrol. 2007 Mar;11(1):41-50
pubmed: 17384997
Clin Exp Nephrol. 2020 Jul;24(7):573-581
pubmed: 32236782
N Engl J Med. 1996 Nov 28;335(22):1636-42
pubmed: 8929360
J Am Soc Nephrol. 2010 Aug;21(8):1355-60
pubmed: 20634296
J Diabetes Complications. 2013 Mar-Apr;27(2):123-7
pubmed: 23182925
Nephrol Dial Transplant. 2018 Jan 1;33(1):138-148
pubmed: 28340221
Diabetes Care. 2019 Oct;42(10):1886-1894
pubmed: 31221677
Diabetes. 2005 Oct;54(10):2983-7
pubmed: 16186402
QJM. 2008 Oct;101(10):821-4
pubmed: 18689428
Nephrol Dial Transplant. 2004 Nov;19(11):2784-8
pubmed: 15328385
Am J Kidney Dis. 2012 Jan;59(1):75-83
pubmed: 22051245
Lancet Diabetes Endocrinol. 2019 Feb;7(2):115-127
pubmed: 30635225
Stat Methods Med Res. 2014 Feb;23(1):74-90
pubmed: 22517270
Diabetes Care. 2020 Jan;43(1):122-129
pubmed: 31796570
Diabetologia. 2005 Nov;48(11):2241-7
pubmed: 16170513
J Am Soc Nephrol. 2010 Apr;21(4):556-63
pubmed: 20167701
Biometrics. 2015 Mar;71(1):102-113
pubmed: 25311240
Am J Kidney Dis. 2014 Dec;64(6):821-35
pubmed: 25441437
Lancet. 2013 Jul 20;382(9888):260-72
pubmed: 23727169

Auteurs

Masayuki Yamanouchi (M)

Nephrology Center, Toranomon Hospital, Tokyo, Japan m.yamanouchi@toranomon.gr.jp twada@m-kanazawa.jp.
Nephrology Center, Toranomon Hospital Kajigaya, Kanagawa, Japan.
Department of Nephrology and Laboratory Medicine, Kanazawa University, Ishikawa, Japan.
Okinaka Memorial Institute for Medical Research, Tokyo, Japan.

Kengo Furuichi (K)

Department of Nephrology, Kanazawa Medical University School of Medicine, Ishikawa, Japan.

Junichi Hoshino (J)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.
Okinaka Memorial Institute for Medical Research, Tokyo, Japan.

Tadashi Toyama (T)

Department of Nephrology and Laboratory Medicine, Kanazawa University, Ishikawa, Japan.

Miho Shimizu (M)

Department of Nephrology and Laboratory Medicine, Kanazawa University, Ishikawa, Japan.

Yuta Yamamura (Y)

Department of Nephrology and Laboratory Medicine, Kanazawa University, Ishikawa, Japan.

Megumi Oshima (M)

Department of Nephrology and Laboratory Medicine, Kanazawa University, Ishikawa, Japan.

Shinji Kitajima (S)

Department of Nephrology and Laboratory Medicine, Kanazawa University, Ishikawa, Japan.

Akinori Hara (A)

Department of Nephrology and Laboratory Medicine, Kanazawa University, Ishikawa, Japan.

Yasunori Iwata (Y)

Division of Infection Control, Kanazawa University, Ishikawa, Japan.

Norihiko Sakai (N)

Department of Nephrology and Laboratory Medicine, Kanazawa University, Ishikawa, Japan.

Yuki Oba (Y)

Nephrology Center, Toranomon Hospital Kajigaya, Kanagawa, Japan.

Shusaku Matsuoka (S)

Nephrology Center, Toranomon Hospital Kajigaya, Kanagawa, Japan.

Daisuke Ikuma (D)

Nephrology Center, Toranomon Hospital Kajigaya, Kanagawa, Japan.

Hiroki Mizuno (H)

Nephrology Center, Toranomon Hospital Kajigaya, Kanagawa, Japan.

Tatsuya Suwabe (T)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.
Nephrology Center, Toranomon Hospital Kajigaya, Kanagawa, Japan.

Naoki Sawa (N)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.
Nephrology Center, Toranomon Hospital Kajigaya, Kanagawa, Japan.

Yukio Yuzawa (Y)

Department of Nephrology, Fujita Health University School of Medicine, Aichi, Japan.

Hiroshi Kitamura (H)

Department of Pathology, National Hospital Organization Chibahigashi National Hospital, Chiba, Japan.

Yoshiki Suzuki (Y)

Health Administration Center, Niigata University, Niigata, Japan.

Hiroshi Sato (H)

JR Sendai Hospital, Miyagi, Japan.

Noriko Uesugi (N)

Department of Pathology, Fukuoka University, Fukuoka, Japan.

Yoshihiko Ueda (Y)

Department of Pathology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.

Shinichi Nishi (S)

Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine School of Medicine, Hyogo, Japan.

Hitoshi Yokoyama (H)

Department of Nephrology, Kanazawa Medical University School of Medicine, Ishikawa, Japan.

Tomoya Nishino (T)

Department of Nephrology, Nagasaki University Hospital, Nagasaki, Japan.

Kenichi Samejima (K)

Department of Nephrology, Nara Medical University, Nara, Japan.

Kentaro Kohagura (K)

Dialysis Unit, University of the Ryukyus School of Medicine, Okinawa, Japan.

Yugo Shibagaki (Y)

Division of Nephrology, Department of Internal Medicine, St Marianna University School of Medicine, Kanagawa, Japan.

Hirofumi Makino (H)

Okayama University, Okayama, Japan.

Seiichi Matsuo (S)

Nagoya University, Aichi, Japan.

Yoshifumi Ubara (Y)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.
Nephrology Center, Toranomon Hospital Kajigaya, Kanagawa, Japan.

Takashi Wada (T)

Department of Nephrology and Laboratory Medicine, Kanazawa University, Ishikawa, Japan m.yamanouchi@toranomon.gr.jp twada@m-kanazawa.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH